SLRN News
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Alumis Stockholders Approve Merger with ACELYRIN
Alumis Stockholders Approve Merger with ACELYRIN
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Alumis and ACELYRIN Announce Amended Merger Agreement
Alumis, ACELYRIN amend proposed merger pact
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, SLRN, BECN on Behalf of Shareholders
SLRN Monitor News

No data
SLRN Earnings Analysis
